Summary:
Learn More About a Clinical Research Study
for Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will test the effectiveness of an investigational medicine for schizophrenia or schizoaffective disorder in adults between the ages of 18 and 45 who have been diagnosed with either schizophrenia or schizoaffective disorder for less than 10 years. Qualified patients will also have had a recent acute exacerbation of schizophrenia (or a psychotic exacerbation of schizoaffective disorder) with evidence of an intensification of psychiatric care of no more than 8 weeks and no signs of lack of treatment response.
This study will last for 17 weeks, and qualified participants will be required to remain in inpatient care for a duration of the first 5 weeks with the option of going outpatient for the rest of the study. This study is a randomized, double-blind, parallel, placebo-controlled trial. This means that some study participants will receive investigational medication, while other participants will receive placebo. The placebo will look exactly like the investigational medication but will not have active ingredients.
You or your loved one may qualify if either of you:
- Are between the ages of 18 and 45
- Have been diagnosed with schizophrenia or schizoaffective disorder for less than 10 years
- Have a recent acute exacerbation of schizophrenia (or a psychotic exacerbation of schizoaffective disorder) with evidence of an intensification of psychiatric care of no more than 8 weeks and no signs of lack of treatment response
- Are hospitalized or require inpatient psychiatric care
- NOTE: If you have been hospitalized for a current exacerbation, the hospitalization must be a maximum of 1 week prior to screening. A study representative will be able to discuss additional details with you.
Additional study requirements and exclusions may apply. A study representative will discuss these with you during the screening period.